{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:27:26Z","timestamp":1793766446627,"version":"4.6.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clgc.2026.102639","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:11:10Z","timestamp":1786633870000},"page":"102639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["De-Escalation Therapy in Metastatic Prostate Cancer: A Retrospective Study on Intermittent ADT and ARPI Combination Treatment"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4290-717X","authenticated-orcid":false,"given":"Barak","family":"Talmor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Baranseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3559-860X","authenticated-orcid":false,"given":"Tomer","family":"Charas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natali","family":"Shirron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Goshenlago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Crumbaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-4580","authenticated-orcid":false,"given":"Anthony","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avivit","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"#cr-split#-10.1016\/j.clgc.2026.102639_bib0001.1","unstructured":"EAU Guidelines. Edn. Presented at the EAU Annual Congress Madrid 2025. EAU Guidelines Office"},{"key":"#cr-split#-10.1016\/j.clgc.2026.102639_bib0001.2","unstructured":"2025. https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/treatment#6-3-management-by-disease-stages. Accessed: October 25, 2025"},{"issue":"5","key":"10.1016\/j.clgc.2026.102639_bib0002","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf095","article-title":"Current landscape in first-line treatment of metastatic hormone sensitive prostate cancer: a cost-effectiveness focused review","volume":"30","author":"\u00c1vila","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2026.102639_bib0003","article-title":"Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2026.102639_bib0004","article-title":"Prostate-specific antigen response as a prognostic factor for overall survival in patients with Prostate cancer treated with androgen receptor pathway inhibitors: a systematic review and meta-analysis","volume":"16","author":"Miszczyk","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2026.102639_bib0005","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","article-title":"Abiraterone","year":"2012"},{"issue":"2","key":"10.1016\/j.clgc.2026.102639_bib0006","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/JU.0000000000003506","article-title":"Coping mechanisms for financial toxicity among patients with metastatic prostate cancer: a survey-based assessment","volume":"210","author":"Joyce","year":"2023","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.clgc.2026.102639_bib0007","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jamaoncol.2021.7987","article-title":"Financial toxicity of cancer treatment","volume":"8","author":"Hussaini","year":"2022","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102639_bib0008","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/bju.12626","article-title":"Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?","volume":"114","author":"Wolff","year":"2014","journal-title":"BJU Int"},{"issue":"14","key":"10.1016\/j.clgc.2026.102639_bib0009","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2026.102639_bib0010","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/JU.0000000000001876","article-title":"Real-world practice patterns and predictors of continuous versus intermittent androgen deprivation therapy use for prostate cancer in older men","volume":"206","author":"Cheung","year":"2021","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102639_bib0011","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.urpr.2014.11.001","article-title":"Adoption of intermittent androgen deprivation therapy for advanced prostate cancer: a population based study in American urology practice","volume":"2","author":"Tsai","year":"2015","journal-title":"Urol Pract"},{"issue":"4","key":"10.1016\/j.clgc.2026.102639_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2026.102536","article-title":"Advances in androgen deprivation therapy\u2013sparing strategies: ongoing studies in metastatic castration-sensitive prostate cancer","volume":"24","author":"Morgans","year":"2026","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2026.102639_bib0013","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.annonc.2025.08.004","article-title":"Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial","volume":"36","author":"Tripathi","year":"2025","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102639_bib0014","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","volume":"77","author":"Matsubara","year":"2020","journal-title":"Eur Urol"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2026.102639_bib0015","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1200\/JCO.2024.42.16_suppl.5079","article-title":"Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: landmark analysis of ENZAMET (ANZUP 1304)","volume":"42","author":"Mc Laughlin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2026.102639_bib0016","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.clgc.2026.102639_bib0017","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"49","key":"10.1016\/j.clgc.2026.102639_bib0018","doi-asserted-by":"crossref","first-page":"19701","DOI":"10.1073\/pnas.1115750108","article-title":"Mathematical modeling of prostate cancer progression in response to androgen ablation therapy","volume":"108","author":"Jain","year":"2011","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1016\/j.clgc.2026.102639_bib0019","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00285-013-0718-y","article-title":"A partial differential equation model and its reduction to an ordinary differential equation model for prostate tumor growth under intermittent hormone therapy","volume":"69","author":"Tao","year":"2014","journal-title":"J Math Biol"},{"issue":"5_suppl","key":"10.1016\/j.clgc.2026.102639_bib0020","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2025.43.5_suppl.310","article-title":"Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: long-term data from a phase III trial","volume":"43","author":"Nabid","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.clgc.2026.102639_bib0021","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS236","article-title":"Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design","volume":"42","author":"Azad","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.clgc.2026.102639_bib0022","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5118","article-title":"A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM\/Alliance A032101)","volume":"42","author":"Choudhury","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:16:29Z","timestamp":1793765789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1558767326001394"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102639","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De-Escalation Therapy in Metastatic Prostate Cancer: A Retrospective Study on Intermittent ADT and ARPI Combination Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102639"}}